To ask the Secretary of State for Health and Social Care, if his Department will make an assessment of the accuracy of reports of a link between paracetamol usage and increased risk of heart conditions.
5 April 2022
The Medicines and Healthcare products Regulatory Agency (MHRA) monitors the safety of all medicines on the market in the United Kingdom. The MHRA recently reviewed a research paper on the effects of paracetamol on blood pressure in patients with hypertension without pain and sought expert advice from the Pharmacovigilance Expert Advisory Group of the Commission on Human Medicines. The experts considered the limitations of the study as it was not representative of the whole population who experience pain and recommended that further evidence is needed to determine effect on blood pressure within the wider population.
The MHRA keeps all new evidence on the safety of paracetamol kept under review. Alternative medicines which can be used to treat pain have known and significant risks on the heart and therefore, the MHRA does not recommend patients change their pain medicine without the advice of their healthcare professional.